Jin-shui Huan-xian Granule in the Treatment of IPF

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

Efficacy and Safety of Jin-shui Huan-xian Granule in the Treatment of IPF

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04187690
• Other study ID #: TCM for IPF
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2020
• Est. completion date: July 30, 2023

Study information

• Verified date: August 2022
• Source: Henan University of Traditional Chinese Medicine
• Contact: Xue-qing Yu, PhD
• Phone: 86-371-66248624
• Email: yxqshi[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate the efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis (IPF), establish the treatment scheme, and obtain the high quality clinical evidences.

Description:

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and ultimately fatal interstitial lung disease. With worsened dyspnea and an increasing loss of pulmonary function, IPF patients will have very poor quality of life. It has also brought an increasing social-economic burden. Researches show that pirfenidone and nintedanib could be effective to IPF, which were also recommended by the guideline. However, the application has been limited by side effects and high prices. It is urgent to develop other effective treatments and strategies to manage IPF. The investigators' previous studies shown that Jin-shui Huan-xian granule could be effective to IPF.

This is a multicerter, randomized, double-blind, placebo-controlled trial to assess the efficacy of Jin-shui Huan-xian granule in reducinig the acute exacerbations, improving exercise capacity, and delaying the disease progression for IPF. After a 2-week wash-out period, 312 patients will be randomly assigned into treatment or control group for 52-week treatment. The primary outcomes are frequencies of acute exacerbation, 6-minute walking test, and percentage of patients with progression-free survival. The secondary outcomes include pulmonary function, all-cause mortality, clinical symptoms, dyspnea score, and quality of life. Safety will also be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 312
• Est. completion date: July 30, 2023
• Est. primary completion date: May 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 85 Years

Eligibility

Inclusion Criteria:

• A confirmed diagnosis stable IPF.

• Age ranges from 40 years to 85 years.

• TCM Syndrome differentiation meets criteria of pattern of Lung Qi deficiency, yin deficiency and inter heat, and lung-kidney qi deficiency.

• Without participanting in any other trial.

• With signed informed consent.

Exclusion Criteria:

• Pregnant, nursing or may become pregnant women.

• Patients with unconscious, dementia or mental disorders.

• Patients with severe cardiac dysfunction.

• Patients with severe liver and kidney diseases.

• Patients with asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism, chronic obstructive pulmonary disease, chronic respiratory failure or other severe respiratory diseases.

• Patients with tumor after resection, radiotherapy or chemotherapy in the past 5 years.

• Patients with severe neuromuscular disorders, severe arthritis or severe peripheral vascular diseases.

• Patients with long-term bedridden.

• Patients who are allergic to any of the treatment drugs.

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• Jin-shui Huan-xian granule
Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
• Jin-shui Huan-xian granule placebo
Jin-shui Huan-xian granule placebo will also be administered 5days on and 2 days off for 52 weeks. The placebo consists 5% of the same components as Jin-shui Huan-xian granule besides dextrin and bitter. The There is no obvious difference in appearance, weight and odor between Jin-shui Huan-xian granule and placebo.

Locations

Country	Name	City	State
China	the First Affiliated Hospital of Henan University of Chinese Medicine	Zhengzhou

Sponsors (1)

Lead Sponsor	Collaborator
Henan University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequencies of acute exacerbations (AEs)	It will be assessed by frequencies of AEIPF-related hospitalizations.	up to 52 weeks.
Primary	Six-minute walking distance(6MWD)	6MWD will be applied to evaluate the exercise capacity. The higher values indicate the better exercise capacity.	Change from baseline 6MWD at week 13, 26, 39 and 52
Primary	Proportion of progressive-free survival	Endpoints of Progressive-free survival include FVC decreased by 10% compared with baseline, or DLCO% decreased by 15%, or death or lung transplantation.	up to week 13, 26, 39 and 52.
Secondary	Pulmonary function	Forced vital capacity (FVC) and diffusing capacity percentage of the predicted value (DLco%) will be applied to assess pulmonary function.	Change from baseline FVC and DLco% at week 26 and 52.
Secondary	All-cause mortality	The all-cause mortality will be calculated in each group at the end of the trial.	up to 52 weeks.
Secondary	Clinical symptoms and Signs	Assessment will be performed by clinical symptom assessment questionnaire. The clinical symptoms to be evaluated in this study include cough, expectoration, chest tightness, shortness of breath, wheezing and cyanosis. A score of 0-3 will be given to every symptom or sign with a higher score indicating a worse conditoin.	Change from baseline clinical symptoms assessment questionnaire scores at week 13, 26, 39 and 52.
Secondary	Dyspnea	Dyspnea will be assessed by modified Medical Research Council (mMRC) scores set up by American Thoracic Society. A score of 0-4 will be given according to the degree of immediate dyspnea. A higher score indicates a worse dyspnea.	Change from baseline mMRC scores at week 13, 26, 39 and 52.
Secondary	COPD assessment test (CAT)	CAT will be used to evaluate quality of life. A total score of 0-40 will be given with a higher score indicating a worse condition.	Change from baseline CAT scores at week 13, 26, 39 and 52.
Secondary	36-item short-form health survey (SF-36) total scores	SF-36 total scores will be used to evaluate quality of life with a total score of 0-100. The higher scores will indicate the better outcomes.	Change from baseline SF-36 scores at week 13, 26, 39 and 52.
Secondary	St. George's respiratory questionnaire (SGRQ) total scores	SGRQ total scores will be used to evaluate quality of life with a total score of 0-100. The higher scores will indicate the worse outcomes.	Change from baseline SGRQ scores at week 13, 26, 39 and 52.
Secondary	A Tool to Assess Quality of life in IPF(ATAQ-IPF)	ATAQ-IPF will be used to evaluate quality of life. There are 13 domains with 74 items with a score of 1-5 for each item. A higher score will indicate a worse health.	Change from baseline ATAQ scores at week 13, 26, 39 and 52.